158 related articles for article (PubMed ID: 11747325)
1. Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma.
Schmidinger M; Wenzel C; Locker GJ; Muehlbacher F; Steininger R; Gnant M; Crevenna R; Budinsky AC
Br J Cancer; 2001 Dec; 85(12):1850-2. PubMed ID: 11747325
[TBL] [Abstract][Full Text] [Related]
2. A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma.
Hong RL; Tseng YL
Cancer Chemother Pharmacol; 2003 May; 51(5):433-8. PubMed ID: 12736762
[TBL] [Abstract][Full Text] [Related]
3. Zinostatin and doxorubicin. A combination phase I study.
Issell BF; Ginsberg SJ; Comis RL
Cancer Clin Trials; 1981; 4(3):323-6. PubMed ID: 6269771
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical trial of liposomal daunorubicin in hepatocellular carcinoma complicating liver cirrhosis.
Daniele B; De Vivo R; Perrone F; Lastoria S; Tambaro R; Izzo F; Fiore F; Vallone P; Pignata S
Anticancer Res; 2000; 20(2B):1249-51. PubMed ID: 10810429
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of repeated percutaneous isolated liver chemoperfusion in local control of unresectable hepatocellular carcinoma.
Ku Y; Tominaga M; Iwasaki T; Fukumoto T; Muramatsu S; Kusunoki N; Sugimoto T; Suzuki Y; Kuroda Y; Saitoh Y
Hepatogastroenterology; 1998; 45(24):1961-5. PubMed ID: 9951848
[TBL] [Abstract][Full Text] [Related]
6. Liposomal doxorubicin: new preparation. Useful in Kaposi's sarcoma.
Prescrire Int; 1998 Jun; 7(35):69-70. PubMed ID: 10342919
[TBL] [Abstract][Full Text] [Related]
7. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.
Hussein MA; Wood L; Hsi E; Srkalovic G; Karam M; Elson P; Bukowski RM
Cancer; 2002 Nov; 95(10):2160-8. PubMed ID: 12412170
[TBL] [Abstract][Full Text] [Related]
8. Transcatheter arterial chemoembolization (TACE) in treatment of hepatocellular carcinoma.
Barone M; Ettorre GC; Ladisa R; Schiavariello M; Santoro C; Francioso G; Vinciguerra V; Francavilla A
Hepatogastroenterology; 2003; 50(49):183-7. PubMed ID: 12630019
[TBL] [Abstract][Full Text] [Related]
9. [Hepatocellular carcinoma with cirrhosis: treatment with doxorubicin. Phase II evaluation].
Barbare JC; Ballet F; Petit J; Poupon R; Darnis F
Bull Cancer; 1984; 71(5):442-5. PubMed ID: 6084528
[TBL] [Abstract][Full Text] [Related]
10. Adriamycin therapy in American patients with hepatocellular carcinoma.
Ihde DC; Kane RC; Cohen MH; McIntire KR; Minna JD
Cancer Treat Rep; 1977 Oct; 61(7):1385-7. PubMed ID: 201380
[No Abstract] [Full Text] [Related]
11. A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma.
Halm U; Etzrodt G; Schiefke I; Schmidt F; Witzigmann H; Mössner J; Berr F
Ann Oncol; 2000 Jan; 11(1):113-4. PubMed ID: 10690399
[TBL] [Abstract][Full Text] [Related]
12. A phase II evaluation of clofazimine plus doxorubicin in advanced, unresectable primary hepatocellular carcinoma.
Falkson CI; Falkson G
Oncology; 1999 Oct; 57(3):232-5. PubMed ID: 10545792
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin (75 mg/m2) for hepatocellular carcinoma: clinical and pharmacokinetic results.
Chlebowski RT; Brzechwa-Adjukiewicz A; Cowden A; Block JB; Tong M; Chan KK
Cancer Treat Rep; 1984 Mar; 68(3):487-91. PubMed ID: 6322986
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of epirubicin in hepatoma.
Shiu W; Mok SD; O SK; Tsao SY; Woo KS; Li A; Leung N; Martin C
Cancer Treat Rep; 1986 Aug; 70(8):1035-6. PubMed ID: 3015405
[No Abstract] [Full Text] [Related]
15. Pegylated liposomal doxorubicin in treating a case of advanced hepatocellular carcinoma with severe hepatic dysfunction and pharmacokinetic study.
Hong RL; Tseng YL; Chang FH
Ann Oncol; 2000 Mar; 11(3):349-53. PubMed ID: 10811504
[TBL] [Abstract][Full Text] [Related]
16. Induction of long-term remission in advanced hepatocellular carcinoma with percutaneous isolated liver chemoperfusion.
Ku Y; Iwasaki T; Fukumoto T; Tominaga M; Muramatsu S; Kusunoki N; Sugimoto T; Suzuki Y; Kuroda Y; Saitoh Y; Sako M; Matsumoto S; Hirota S; Obara H
Ann Surg; 1998 Apr; 227(4):519-26. PubMed ID: 9563540
[TBL] [Abstract][Full Text] [Related]
17. Adriamycin and 5-fluorouracil in the treatment of advanced hepatoma: a Southwest Oncology Group study.
Baker LH; Saiki JH; Jones SE; Hewlett JS; Brownlee RW; Stephens RL; Vaitkevicius VK
Cancer Treat Rep; 1977 Nov; 61(8):1595-7. PubMed ID: 200359
[No Abstract] [Full Text] [Related]
18. 4'Epidoxorubicin (epirubicin): activity in hepatocellular carcinoma.
Hochster HS; Green MD; Speyer J; Fazzini E; Blum R; Muggia FM
J Clin Oncol; 1985 Nov; 3(11):1535-40. PubMed ID: 2997408
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl).
Working PK; Dayan AD
Hum Exp Toxicol; 1996 Sep; 15(9):751-85. PubMed ID: 8880211
[No Abstract] [Full Text] [Related]
20. Neoadjuvant chemotherapy and orthotopic liver transplantation for hepatocellular carcinoma.
Holman M; Harrison D; Stewart A; Stone M; Goldstein R; Husberg B; Klintmalm G
N J Med; 1995 Aug; 92(8):519-22. PubMed ID: 7675334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
